{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:44:36Z","timestamp":1785905076072,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031935","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172798"],"award-info":[{"award-number":["82172798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472749"],"award-info":[{"award-number":["82472749"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2024SF-ZDCYL-02-08"],"award-info":[{"award-number":["2024SF-ZDCYL-02-08"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clbc.2026.04.014","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:12:27Z","timestamp":1776787947000},"page":"141-152.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Typical Somatic Gene Mutation Characteristics on Homologous Recombination Deficiency in Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3388-297X","authenticated-orcid":false,"given":"Jinsui","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clbc.2026.04.014_bib0001","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.18632\/aging.202724","article-title":"PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival","volume":"13","author":"Shao","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"10074","key":"10.1016\/j.clbc.2026.04.014_bib0002","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The great immune escape: understanding the divergent immune response in breast cancer subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0004","doi-asserted-by":"crossref","first-page":"188521","DOI":"10.1016\/j.bbcan.2021.188521","article-title":"DNA damage response inhibitors: an avenue for TNBC treatment","volume":"1875","author":"Jin","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.014_bib0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0006","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.014_bib0007","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tips.2010.06.001","article-title":"Targeting homologous recombination repair defects in cancer","volume":"31","author":"Evers","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clbc.2026.04.014_bib0008","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.10.021","article-title":"Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective","volume":"179","author":"Herzog","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2026.04.014_bib0009","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, homologous recombination deficiencies, and synthetic lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.clbc.2026.04.014_bib0010","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clbc.2026.04.014_bib0011","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.014_bib0012","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/djae129","article-title":"Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study","volume":"116","author":"Dent","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.014_bib0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.014_bib0016","first-page":"290","article-title":"Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2026.04.014_bib0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/1471-0528.17324","article-title":"Genomic Scar Score: a robust model predicting homologous recombination deficiency based on genomic instability","volume":"129","author":"Yuan","year":"2022","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.014_bib0018","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pathol.2023.12.413","article-title":"Observations from a national sample exchange program for molecular haematology testing","volume":"56","author":"Gould","year":"2024","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0019","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"10","key":"10.1016\/j.clbc.2026.04.014_bib0020","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clbc.2026.04.014_bib0021","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/35080033","article-title":"Linking class-switch recombination with somatic hypermutation","volume":"2","author":"Kinoshita","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0022","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41588-024-02039-4","article-title":"Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations","volume":"57","author":"Funk","year":"2025","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0024","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1101\/gad.9.2.204","article-title":"p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest","volume":"9","author":"Ewen","year":"1995","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41418-024-01259-9","article-title":"Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?","volume":"32","author":"Janic","year":"2025","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.clbc.2026.04.014_bib0027","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2024.03.006","article-title":"Genetic interactions reveal distinct biological and therapeutic implications in breast cancer","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0028","doi-asserted-by":"crossref","first-page":"pbae009","DOI":"10.1093\/pcmedi\/pbae009","article-title":"TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study","volume":"7","author":"Huang","year":"2024","journal-title":"Precis Clin Med"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0029","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40246-022-00447-3","article-title":"Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1\/2 mutations","volume":"17","author":"Kim","year":"2023","journal-title":"Hum Genomics"},{"issue":"6","key":"10.1016\/j.clbc.2026.04.014_bib0030","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan","year":"2021","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.clbc.2026.04.014_bib0031","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ygyno.2020.12.007","article-title":"Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations","volume":"160","author":"Ghezelayagh","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2026.04.014_bib0032","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1128\/MCB.22.12.4280-4292.2002","article-title":"BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets","volume":"22","author":"MacLachlan","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0033","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-021-00253-5","article-title":"Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development","volume":"7","author":"Huo","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0034","first-page":"1","article-title":"PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: four case reports","volume":"23","author":"Collot","year":"2021","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s40001-025-02520-8","article-title":"Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice","volume":"30","author":"Du","year":"2025","journal-title":"Eur J Med Res"},{"issue":"5","key":"10.1016\/j.clbc.2026.04.014_bib0036","doi-asserted-by":"crossref","first-page":"oyaf089","DOI":"10.1093\/oncolo\/oyaf089","article-title":"Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers","volume":"30","author":"Jeon","year":"2025","journal-title":"Oncologist"},{"issue":"36","key":"10.1016\/j.clbc.2026.04.014_bib0037","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.04.014_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4441-3","article-title":"Mechanisms of immune evasion in breast cancer","volume":"18","author":"Bates","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.04.014_bib0039","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","article-title":"Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial","volume":"25","author":"Fan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.04.014_bib0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat Cancer"},{"issue":"728","key":"10.1016\/j.clbc.2026.04.014_bib0041","doi-asserted-by":"crossref","first-page":"eadg7740","DOI":"10.1126\/scitranslmed.adg7740","article-title":"Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer","volume":"16","author":"Ding","year":"2024","journal-title":"Sci Transl Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:50:59Z","timestamp":1785901859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1526820926000686"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.014","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Typical Somatic Gene Mutation Characteristics on Homologous Recombination Deficiency in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}